Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.

Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.